Pembrolizumab a promising option for MIUC patients after radical surgery

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems

Stockholm3 offers a promising avenue for personalised risk-based prostate cancer diagnosis

Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP

Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC

Lenvatinib and pembrolizumab show promising efficacy in first-line treatment of aRCC

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC

Combination of cabozantinib and atezolizumab shows moderate activity in treating metastatic adrenocortical carcinoma